HIV Webinar Access
The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test recently received FDA approval on new performance data which demonstrates earlier detection in seroconversion panels when compared to 3rd generation EIA. When compared with over 200 samples across 23 different seroconversion panels, the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test shows comparable results to 3rd generation automated testing, a significant improvement from the initial launch of the product in 2002. During this webinar, we will discuss the following:
- The new FDA-approved performance data
- Compare results from new OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test to third-generation automated EIA's
- Discuss benefits of utilizing a rapid point-of-care test for HIV
- Discuss benefits of the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
The videos you have selected are restricted to registered video users of the OraSure Resource Center. Please log in or register your account for video access. Your OraSure Representative or Customer Care can assist you in upgrading your privileges if you still are unable to access.